Novosyn® Quick in Patients Undergoing Episiotomy Closure
Launched by AESCULAP AG · Feb 9, 2022
Trial Information
Current as of May 29, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the use of Novosyn® Quick, a type of surgical thread, in women who have had an episiotomy, which is a surgical cut made during childbirth to help deliver the baby. The researchers want to see how well this specific thread works for closing the wound after the procedure. The trial is currently recruiting participants who are women aged between 65 and 74 years old and who had an episiotomy at the Hospital General de Catalunya in Spain between January 2020 and December 2020.
If you or someone you know fits this description and is interested in participating, there are no specific health restrictions that would prevent someone from joining. Those who participate can expect to contribute to important research that could help improve care for future patients undergoing similar procedures. This study is a retrospective analysis, meaning it will review and analyze information from patients who have already undergone the procedure, rather than enrolling new patients for a trial. This could provide valuable insights into the effectiveness of Novosyn® Quick in episiotomy closures.
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Women who underwent an indicated episiotomy between January 2020 - December 2020 at the Hospital General de Catalunya (Sant Cugat del Vallès, Spain) and received Novosyn® Quick
- Exclusion Criteria:
- • No exclusion criteria have been set
About Aesculap Ag
Aesculap AG is a prominent global medical device manufacturer specializing in surgical instruments, implants, and innovative healthcare solutions. With a rich history rooted in excellence and innovation, Aesculap AG is dedicated to advancing surgical practices through cutting-edge technology and a commitment to improving patient outcomes. The company collaborates with healthcare professionals and institutions to conduct clinical trials that evaluate the safety and efficacy of its products, ensuring that they meet the highest standards of quality and performance. Through its rigorous research and development initiatives, Aesculap AG aims to contribute significantly to the field of medicine and enhance the standards of surgical care worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Sant Cugat Del Vallès, Catalunya, Spain
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials